NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Valuation Check As FDA Grants Priority Review For Olezarsen
Ionis Pharmaceuticals (IONS) is back in focus after the US FDA accepted a Priority Review for its supplemental New Drug Application for olezarsen in severe hypertriglyceridemia, placing a key RNA medicine under a tighter regulatory timeline.
See our latest analysis for Ionis Pharmaceuticals.
Despite the latest FDA Priority Review, Ionis Pharmaceuticals' recent share price momentum has cooled, with a 30 day share price return of 12.88% and a year to date share price return decline of 7.07%,...